Eric Faulkner, RTI Health Solutions Director of US Market Access and Reimbursement, will speak at the CBI’s 2nd Annual Forum on Evidence-Based Medicine for the BioPharmaceutical and Medical Devices Industries Conference to be held in King of Prussia, PA on November 19-20, 2008. This forum will assemble stakeholders to address current challenges and opportunities regarding evidence-based medicine, health technology assessment and implications for health technology access and market uptake.
Mr. Faulkner will lead a discussion entitled
Personalized Medicine at the Tipping Point: Designing Evidence-based Processes that Enable Innovation and Address Decision Maker Needs. A description of the session is provided below:
Evidence-based practice and policy for emerging molecular diagnostics and emerging personalized medicine approaches has proven challenging for payors and other health technology decision makers. While in some instances stakeholders have resisted personalized medicine, it is clear that manufacturers, payors, physicians and patients will increasingly embrace such approaches in light of the significant quality and cost challenges facing U.S. and global health systems. For such rapidly evolving innovative technologies, it is clear that one-size-fits-all approaches are insufficient in a health technology assessment environment largely oriented towards characterizing the value of treatments. Decision-maker preferences for historical evidence hierarchy-based approaches, where the randomized controlled trial (RCT) is considered ideal, have further complicated evolution of appropriate and alternative health technology assessment (HTA) practices that take into account the unique attributes of diagnostics and personalized medicine. This session explores current practice and policy issues at the intersection of evidence-based practice and personalized medicine and considers practical approaches that balance our growing need for information with the practical realities and resources required for developing and commercializing increasingly personalized health technologies.
Mr. Faulkner’s responsibilities at RTI Health Solutions (RTI-HS) involve evaluation of US and international pricing and reimbursement issues, health technology assessment practices, product reimbursement and commercialization strategies and changing health policy. He has recently served as an expert advisor to the Personalized Medicine Subcommittee of the President’s Council of Advisors on Science and Technology and the Personalized Health Care Initiative of the US Department of Health and Human Services. He is also serving as a lead editor for an upcoming book entitled Medical Device and Diagnostics Outcomes Research: Issues and Good Research Practices, sponsored by the US Medical Device and Diagnostics Council of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR).
In addition to responsibilities at RTI, Mr. Faulkner also serves as Director of the Genomic Biotech Institute (GBI) of the National Association of Managed Care Physicians (NAMCP) and Editor-in-Chief of the GBI special section of the Journal of Managed Care Medicine, Genomics and Biotechnology.
If you would like to speak with Eric regarding this conference or pre-arrange a meeting, please contact him at 919-541-6772 or firstname.lastname@example.org..